Nephros (NEPH) Liabilities and Shareholders Equity (2010 - 2026)
Nephros (NEPH) posted quarterly Liabilities and Shareholders Equity of $13.8 million for Q1 2026, up 17.12% year-over-year from $11.8 million in Q1 2025, and up 1.12% quarter-over-quarter from $13.6 million in Q4 2025.
Nephros (NEPH) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Nephros' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $13.8 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 17.12% year-over-year to $13.8 million; the TTM figure through Mar 2026 stood at $52.9 million (up 19.0% YoY), while the FY2025 annual figure was $13.6 million, up 21.69% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $13.8 million, up from $13.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $15.5 million in Q1 2022, with the low at $10.4 million in Q2 2023.
- The 5-year median for Liabilities and Shareholders Equity is $11.4 million (2024), against an average of $12.1 million.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity slumped 37.68% in 2022, then increased 27.55% in 2025.
- Nephros' Liabilities and Shareholders Equity stood at $11.0 million in 2022, then advanced by 7.84% to $11.9 million in 2023, then fell by 5.49% to $11.2 million in 2024, then gained by 21.69% to $13.6 million in 2025, then advanced by 1.12% to $13.8 million in 2026.
- Business Quant data shows NEPH's Liabilities and Shareholders Equity at $13.8 million in Q1 2026, $13.6 million in Q4 2025, and $13.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 20.88 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 50.73 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 31.10 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 8.97 Bn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 39.35 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 4.08 Bn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 14.24 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 12.48 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 19.79 Bn |
| 10 | Nephros | 45.71 Mn | 41.01 Mn | 4.03 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.77 Mn |
| Mar 31, 2026 | 13.79 Mn |
| Dec 31, 2025 | 13.64 Mn |
| Sep 30, 2025 | 13.25 Mn |
| Jun 30, 2025 | 12.24 Mn |
| Mar 31, 2025 | 11.78 Mn |
| Dec 31, 2024 | 11.21 Mn |
| Sep 30, 2024 | 10.39 Mn |
| Jun 30, 2024 | 11.10 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Dec 31, 2023 | 11.86 Mn |
| Sep 30, 2023 | 10.92 Mn |
| Jun 30, 2023 | 10.39 Mn |
| Mar 31, 2023 | 10.93 Mn |
| Dec 31, 2022 | 11.00 Mn |
| Sep 30, 2022 | 11.34 Mn |
| Jun 30, 2022 | 14.95 Mn |
| Mar 31, 2022 | 15.53 Mn |
| Dec 31, 2021 | 17.65 Mn |
| Sep 30, 2021 | 17.82 Mn |